How this document came to be
About this sample
MITF is a transcription factor that activates cell-cycle and survival genes and is a master regulator of melanocyte development. In people with the E318K mutation, MITF loses the ability to be co-repressed by epigenetic regulatory complexes and turns into a constitutive activator. This leads to a predisposition of this patient group to skin and renal cancers.
Our client, a scientist and a bearer of the E318K mutation themselves, wanted to create a survey of the knowledge of the mechanisms and the recent progress in treatment approaches for tumours associated with the MITF E318K mutation.
The client wanted to use this report to keep them posted on the most recent and advanced treatment and cancer-prevention opportunities associated with their mutation.
The client was pleasantly surprised by the broad scope of the most advanced therapeutic options covered by the report, some of which they were not aware of.
The brief we developed with the client
“Produce an extended, detailed review of the MITF E318K mutation: its mechanism of action and the most promising therapeutic approaches. Trace how the loss of the SUMOylation brake reprograms MITF activity, and connect those molecular changes to actionable vulnerabilities across melanoma and renal cell carcinoma.”
A note on deliverables
The PDF document itself is a small part of our full research output. The client deliverables include PRISMA-compliant literature search strategies, PubMed retrievals, writing blocks the client may use for reconstruction and revision while catering to different reporting formats, a reference database compatible with major bibliographic software, Python code for data extraction and analysis, and more.
Our team has verified the bibliographic references and checked the quantitative claims against their cited sources. This document is a literature synthesis intended to support manuscript development; it is not itself a peer-reviewed publication, and nothing in it constitutes medical advice.
Provenance
Prepared and published by Cellformatica with the client’s permission. © 2026 Cellformatica.
